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Background and Objectives. The optimal method for liv-
er biopsy in patients with simultaneous bone marrow and
liver impairment has not yet been established. New
approaches (e.g. imaging-guided methods) for this pro-
cedure are needed. In spite of coagulopathy, immuno-
suppression, anemia or ascites, we histologically charac-
terized liver damage in a series of bone marrow trans-
planted patients using color-Doppler ultrasonography,
which permits very keen visualization (and assessment)
of hepatic parenchyma and vessels, and a fine needle for
percutaneous biopsy. 
Design and Methods. We performed percutaneous liver
biopsy using a Menghini-type automatic very fine cutting
needle (1.2 mm, 18G) under color ultrasound guidance
in 16 bone marrow transplanted adult patients consecu-
tively seen in our units from 1998 to 2001. The patients
had clinically defined diffuse serious liver damage; liver
biopsy was performed between 3 and 10 months after
allogeneic (n= 11) or autologous (n= 5) transplantation.
Results. Fifteen patients tolerated the procedure well and
had no discomfort, while one patient developed intra-
hepatic hemorrhage. All liver biopsies were suitable for
histologic examination and informative, revealing the spe-
cific etiology of liver damage: graft-versus-host disease in
six patients, drug toxicity in five, hepatitis C virus acute
reactivation in two, and in one each vanishing bile duct
syndrome, nodular regenerative hyperplasia and hemo-
chromatosis. Biopsy detected potentially injurious con-
comitant factors, e.g., occult intrahepatic hepatitis B virus
infection and reactivation. Histology radically changed the
presumptive clinical diagnosis in 10 of the 16 patients
and led to successful treatment changes in six.
Interpretation and Conclusions. Percutaneous biopsy with
a small cutting needle under color ultrasound guidance
carries a low risk of complications and provides reliable
information regarding liver histology in critically ill
patients, in the early stage after bone marrow transplan-
tation. We suggest including this imaging-guided mini-
invasive procedure to the standard work-up of post-trans-
plant liver damage. 
©2002, Ferrata Storti Foundation
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Liver complications are a serious clinical prob-lem in patients with hematologic malignan-cies undergoing bone marrow transplantation
(BMT). Morbidity and mortality due to hepatic fail-
ure appear to have a significant impact on sur-
vival of transplanted patients.1,2 A variety of fac-
tors may induce liver damage, a combination of
which may occur simultaneously or sequentially
in the same patient.1,2 The etiology of liver damage
is evaluated nowadays by non-invasive studies,
while histology is reserved for occasional cases,
especially when serious bone marrow impairment
co-exists.3,4 We investigated the role of color ultra-
sound-guided percutaneous biopsy using a fine
cutting needle with automatic aspiration, for eti-
ologic diagnosis of liver damage in patients after
BMT for hematologic malignancies, and compared
the histologic diagnosis with the presumptive clin-
ical diagnosis.
Design and Methods
Over the last 4 years, sixteen consecutive
patients who had undergone BMT presented with
severe or life-threatening liver damage, in the
absence of focal lesions (Table 1). Their median
serum transaminase level was 635 U/L [(range 90-
3396; upper normal limit (UNL)= 40)], total biliru-
bin 10 mg/dL (1.6-50; UNL= 1), alkaline phos-
phatase 535 U/L (100-900; UNL= 275) and glu-
tamyl-transpeptidase 720 U/L (47-2000; UNL=
50). Two patients had grade II hepatic ence-
phalopathy. Except three who had shown mild
hypertransaminasemia (2.5 × normal value), all
patients had had normal liver function tests before
their transplant. For allo-transplanted patients,
graft-versus-host disease (GvHD) prophylaxis was
cyclosporin A (for 6 months) and short-course
methotrexate.5 Evaluation before biopsy included
history, physical examination, serum bilirubin, liv-
er enzyme determination, iron status, search for
viral markers, blood count, prothrombin time (PT)
and partial thromboplastin time, fibrinogenemia,
and color-Doppler ultrasound scans.6-9 The clinical
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diagnosis of liver damage, which was determined
via these non-invasive studies, was subsequently
compared with the histologic diagnosis. We con-
sidered contraindications to biopsy massive ascites,
bile duct dilation or absolute absence of patient
co-operation.10 A platelet transfusion (single-donor
pheresis unit) was administered on the day of the
procedure if the platelet count was less than
50×109/L. For patients with PT < 50%, coagulation
factors (Protromplex, Immuno AG, Wien, Austria, 5-
10 U/kg i.v.) were administered on the day before
biopsy. Vitamin K, broad-spectrum antibiotics and
tranexamic acid were given to all patients the day
before, the day of and the day after the procedure.
A Hitachi instrument equipped with color-Doppler
(EUB 525, Tokyo, Japan), a 2.5/3.5 MHz broad band
curvilinear probe and puncture adaptor was used.
After informed consent, a pre-biopsy color ultra-
sound map of intrahepatic vascularization was
obtained using a large-size color box and parame-
ters adjusted for slow-flow detection (1.5 Hz CF,
100 Hz band filter, high color persistence).11,12 The
information related to intrahepatic angioarchitec-
ture was used to select the target zone for biopsy:
the needle was preferably directed through rela-
tively hypoperfused tissue, to avoid intervening
vessels. After fasting and during slight inspiration,
the procedure was carried out with an aseptic
technique (sterile cover of the probe and sterile
gel; Parker laboratories, Fairfield, NJ, USA) and
cutaneous anesthesia, by two members of the
hematology staff, using a 1.2 mm (18G) diameter
Menghini cutting needle 150 mm in length with
automatic aspiration (Biomol HS-Hospital; Rome,
Italy). After biopsy, the patients remained in a
supine position for 1 hour with monitoring of vital
signs every 15 minutes; then abdominal ultrasound
scan was repeated to look for procedure-related
complications. In all cases, a repeat blood count
was performed the next day.13 Histopathologic
examination was performed in a single Pathology
Unit (S. Salvatore Hospital, Pesaro, Italy) and was
blind to the patient's clinical conditions. Biopsies
were considered diagnostic if a minimum of three
portal spaces were present to permit evaluation of
fibrosis and necrotic-inflammatory changes.14,15 The
histologic sections were analyzed according to
standard methods;2,16 in addition, immunoperoxi-
dase staining for HBsAg and HBcAg, and in situ
hybridization for HBV-DNA were carried out using
standard procedures.
Results
At the time of the biopsy, all patients had abnor-
mal blood count: neutrophils ranged between 0.8
and 2.4×109/L (median 1.2), lymphocytes 0.2-
2.0×109/L (median 1.0), hemoglobin 7.5-11 g/dL
(median 10) and platelets 20-80×109/L (median
60). Four patients had mild to moderate ascites.
Eleven patients were receiving steroids and CsA.
Four patients received single-donor pheresis units
Post-BMT liver damage histology 
Table 1. Patients’ characteristics at the time of biopsy.
Pt Age (years), Disease, Preparative Months Platelet Viral status Drugs in use
sex BMT regimen* from BMT count (×109/L)
1 45, M AML, Allo BU-CY 7 80 negative PDN 50, CsA 100
2 55, M CML, Allo BU-CY 5 80 HBsAb+ PDN 75, CsA 300, FLC 300
3 37, M CML, Allo BU-CY 9 80 negative PDN 100, CsA 300, FLC 300
4 40, M AML, Allo BU-CY 6 80 negative PDN 25, CsA 300
5 30, M AML, Allo BU-CY 6 45t negative PDN 50, CsA 150
6 20, F ALL, Allo BU-CY 6 60 negative PDN 25, CsA 100
7 30, F AML, Allo BU-CY 8 60 HBsAb+/cAb IgG+ PDN 75, CsA 150
8 21,F CML, Allo BU-CY 3 45t negative MPD 60, CsA 150, ITRA 300, ACY 1500
9 38, M CML, Allo BU-CY 10 40t negative MPD 625, CsA 300, FLC 300, ACY 1500, TPN 
10 55,M NHL, Allo THIO-CY 5 20t HBsAb+/eAb+/cAb IgG+ MPD 625, CsA 100, ITRA 200, ACY 1500, TPN 
11 27, M HL, Allo BU-CY 5 80 HBsAb+ PDN 25, CsA 300, CLA 1000, ITRA 400, CYC 1500
12 40, F AML, Auto BU-CY 7 80 negative none
13 38, F HL, Auto BEAM 7 80 negative none
14 35, M NHL, Auto THIO-CY 3 60 HBsAb+/eAb+/cAb IgG+ none
15 52, M AML, Auto BU-CY 7 60 HCV-Ab+/RNA+ none
16 44, M HL, Auto BEAM 4 60 HCV-Ab+/RNA+ none
Allo= allogeneic BMT from HLA-identical sibling, Auto= autologous, CML= CML in chronic phase, NHL= aggressive NHL; PDN= prednisone mg/day, CsA=  cyclosporin A
mg/day, FLC= fluconazole mg/day, MPD= methylprednisolone mg/day, ITRA= itraconazole mg/day, ACY= acyclovir mg/day, TPN= total  parenteral nutrition, CLA= clary-
thromycin mg/day. *According to standard doses (references #8 and #27); = patients who received platelet transfusion.
654
haematologica vol. 87(6):june 2002
M. Picardi et al.
the day of the biopsy (one for each patient) and
two of them received additional pheresis units dur-
ing and the day after the procedure (Table 1). A
single patient (n# 10) received coagulation factor
concentrate pre-biopsy, having a PT 40%. 
Biopsy-related procedure and complications
In 14 patients the liver biopsy was performed in
a day-hospital regimen; the remaining 2 were in-
patients because of acute liver failure, and biopsy
was carried out directly at the patient's bedside.
The biopsy was performed 7 to 14 days (median 8)
after the onset of signs of liver dysfunction not
responding to medical management. The average
time required for the procedure (including color
ultrasound study) was about 35 minutes; the cut-
ting needle crossed at least 5 cm of the right (12
cases) or left (4 cases) hepatic lobe by a sub-costal
approach. Except a single case, neither major nor
minor complications were observed during or after
the biopsy; no patient required a surgical inter-
vention and no biopsy-related peritoneal bleeding,
peritonitis, sepsis or pain requiring analgesics
occurred. All day-hospital patients left the hospi-
tal after 3 hours and maintained telephone contact
for 24 hours; no biopsy-related hospitalization was
needed for any of them. One of the in-patients
(#10), who had a pre-biopsy total bilirubin 50
mg/dL and transaminase 1500 U/L developed
abdominal pain, tachycardia and hypotension two
hours after the biopsy. Ultrasound scan detected a
large intrahepatic hematoma in the right lobe,
without evidence of intraperitoneal hemorrhage;
blood count showed severe anemia (6 g/dL) and
thrombocytopenia (30×109/L). Intravenous fluids,
three units of blood and two single-donor phere-
sis units were promptly administered. Two days lat-
er an aggravation of liver failure (grade IV
encephalopathy) occurred and the patient died,
despite resolution of the anemia. A post-mortem
was not performed.
Histologic features 
Histologic results were obtained 4 to 6 days
(median 5) after biopsy. In all patients a single pass
produced diagnostic tissue considered sufficient
Table 2. Clinical and histologic diagnoses, and changes in therapeutic approach following liver biopsy.
Pt. Clinical diagnosis Histological diagnosis Change in treatment Patient outcome (months from biopsy)
1 GvHD GvHD increase steroids and CsA liver function normalization in 8 weeks (40+)
2 GvHD drug toxicity discontinue drugs in use liver function normalization in 10 weeks (38+)
3 GvHD NRH discontinue drugs in use no liver function improvement (30+)
4 GvHD GvHD increase steroids and CsA liver function normalization in 7 weeks (28+)
5 GvHD GvHD increase steroids and CsA liver function normalization in 9 weeks. Died of leukemia relapse (25)
6 GvHD GvHD increase steroids and CsA liver function improvement. Died of leukemia relapse (18) 
7 GvHD GvHD and occult HBV infection increase steroids, liver function improvement (18+)
introduce lamivudine *
8 GvHD drug toxicity discontinue drugs in use liver function improvement (18+)
9 GvHD drug toxicity discontinue drugs in use liver function improvement. Died of leukemia relapse (2)
10 GvHD drug toxicity and occult HBV infection none expired for acute liver failure two days after biopsy
11 drug toxicity GvHD introduce steroids and CsA liver function normalization in 8 weeks (28+) 
12 drug toxicity drug toxicity none liver function normalization in 10 weeks (22+)
13 lymphoma involvement VBDS introduce UDCA liver function improvement (8+)
14 lymphoma involvement hemochromatosis and occult HBV introduce lamivudine* liver function improvement. Died of lymphoma relapse (2)
reactivation 
15 HCV+ cirrhosis and HCV+ active chronic hepatitis none (§) no liver function improvement (18+)
drug toxicity
16 HCV+ cirrhosis and HCV+ active chronic hepatitis none (§) no liver function improvement (4+)
drug toxicity
GvHD= chronic GvHD, NRH= nodular regenerative hyperplasia, VBDS= vanishing bile duct syndrome; UDCA= ursodeoxycholic acid 15 mg/kg/day orally. *100 mg/day orally;
(§) the patient refused α-interferon and ribavirine treatment.
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for histology. The samples obtained measured
about 1 mm in diameter and ranged in length from
20 to 30 mm (median 25). All liver biopsies were
informative, establishing the specific etiology of
liver damage in all patients and completely or par-
tially changing the presumptive clinical diagnosis
in 11 of them (69%) (Table 2). Six patients had
chronic GvHD, involving skin and lungs in 4 of them
and limited to the liver in two. Five patients were
suffering from direct drug toxicity demonstrated
by the presence of typical toxic alterations (steato-
sis, binucleated hepatocytes and cholestasis) in the
absence of signs of inflammation (portal space
infiltration or fibrosis, bile duct proliferation). The
two HCV-Ab+ patients showed active chronic
hepatitis characterized by portal space inflamma-
tion and fibrosis, and moderate hepatocyte necro-
sis related to acute reactivation of HCV infection
(serum HCV-RNA: 0.25 copies ×10-6/mL, in both
patients). One patient showed mild vanishing bile
duct syndrome characterized by loss of interlobu-
lar bile ducts in about 30% of portal spaces, with-
out evidence of infiltration by the basic disease
(Hodgkin's lymphoma). One patient had developed
nodular regenerative hyperplasia. One patient had
active chronic hepatitis characterized by portal
space inflammation, fibrosis and moderate hepa-
tocyte necrosis related to severe iron overload. As
a concomitant abnormal finding, liver biopsy
detected an intrahepatic reservoir of HBV in three
serum HBsAg-negative patients who had had only
one previous viral contact (Table 1). In particular,
two of them had occult HBV infection (intracyto-
plasmic HBV-DNA in about 30% of hepatocytes),
while the other showed occult viral reactivation
(intracytoplasmic HBsAg and HBV-DNA in about
40% of hepatocytes) (Figure 1).
Post-BMT liver damage histology 
Figure 1. Representative histologic findings obtained after bone marrow transplant by fine-needle liver biopsy. (A) Intracyto-
plasmic HBsAg (immunoperoxidase staining) and (B) HBV-DNA (in situ hybridization) in a case of occult HBV reactivation; (C)
lymphocyte infiltration in a portal space with cytolysis, lymphocyte satellitosis and bile ductule degeneration in a case of severe
GvHD; (D) intracytoplasmic HBV-DNA suggesting an occult HBV infection in the same patient as in (C).
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Patients’ outcome
Changes in therapeutic approach following biop-
sy and outcome for each patient are shown in Table
2. Altogether, in 12/16 patients the results of the
histologic examination led to treatment modifica-
tion which was followed by signs of improved or
normalized liver function in eleven. 
Discussion
We tested the feasibility, associated risk and
diagnostic accuracy of an imaging-guided mini-
invasive procedure used to assess the specific eti-
ology of liver damage in a small series of critically
ill patients in the early phase post-BMT. The pro-
cedure was easily and quickly carried out directly
in the hematology unit by members of the hema-
tology staff trained in diagnostic ultrasonography.
Despite the reported significantly increased risk of
percutaneous biopsy-related complications,10,17,18
this occurred in only one case. Intrahepatic
hematoma is a severe but non-fatal complication
of percutaneous biopsy; conservative medical man-
agement is generally sufficient for recovery.10,13,19
However, in our patient there was strict time-rela-
tionship between biopsy-related hematoma/ane-
mia/hypotension and fatal liver failure. We cannot
exclude that the biopsy played a role as a co-fac-
tor in precipitating the hepatic deterioration in this
patient with underlying life-threatening liver dis-
ease related to non-viral (drug toxicity) and viral
(occult HBV infection) agents.20 Given the small
number of patients, we cannot make absolute con-
clusions regarding safety, but we would like to
underline the low incidence of complications and
the excellent tissue samples obtained,21 which were
successful and informative in all instances. About
70% of presumptive clinical diagnosis were cor-
rected by the histologic diagnosis; in most cases
the biopsy-guided therapeutic changes led to
improvement or normalization of liver function.
Chronic GvHD presented itself as acute hepatitis in
patients under tapering immunosuppression or
receiving no immunosuppression, as already
reported in other series.22 Drug toxicity due to
immunosuppressants, antimicrobials, transfusions
or total parenteral nutrition was a frequent cause
of damage, particularly after allogeneic BMT. Clin-
ically significant liver damage related to acute HCV
reactivation occurred in two non-cirrhotic HCV-
infected patients, suggesting a more aggressive
behavior of the virus when significant alteration
of the immune response is induced in the host.23
The intrahepatic presence of HBV genome in
absence of signs of viral activity in the serum in
three cases is intriguing; further dedicated studies
are warranted in order to investigate a link
between an occult intrahepatic HBV reservoir and
triggering of hepatocellular injury.20,24
In conclusion, our study confirms that correct
diagnosis and therapeutic management of a trans-
planted patient with serious liver damage should be
guided by histologic assessment,10,16,22 in order to
avoid mistaken diagnoses and unnecessary, empir-
ical and potentially injurious treatments. We sug-
gest adding our imaging-guided mini-invasive pro-
cedure to the standard diagnostic work-up of post-
BMT liver damage. Other more invasive, complex
and expensive procedures used to obtain hepatic
tissue, such as transjugular or laparoscopic biop-
sy,25,26 should be limited to patients in the very ear-
ly post-transplant phase and/or with very severe
coagulopathy unresponsive to transfusion of
hemoderivatives.18
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What is already known on this topic
Nowadays, liver damage in critically ill patients after BMT
may be evaluated by a transjugular or laparoscopic biop-
sy. These invasive methods are complex, expensive and
not exempt from complications.
What this study adds
This study shows that percutaneous biopsy with a small
cutting needle under ultrasound guidance is a good
method to obtain hepatic tissue samples in these
patients.
Potential implications for clinical practice
This mini-invasive procedure permits a correct diagno-
sis to be established in most cases and consequently an
adequate therapeutic approach to be adopted.
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